Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jiedu Sangen granules for postoperative stage II–III colorectal cancer
ChiCTR-OIC-16008986Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2015
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of Jiedu Sangen Decoction in colorectal cancer (CRC) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Disease-free survival. Planned start Jan 2015; status: not yet recruiting.
02
Drugs
Jiedu Sangen Decoction
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR-OIC-16008986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16008986.